Luminex, UNM Alliance May Make Flow Cytometry an Attractive Option for High-Throughput Drug Screening | GenomeWeb

NEW YORK, May 25 (GenomeWeb News) - An ongoing collaboration between Luminex and the University of New Mexico at Albuquerque may lead to an ultra-high-throughput version of Luminex's xMAP assay platforms, and may help increase the throughput of flow cytometers to the point where big pharma may find them attractive options for drug-screening applications, not just basic research.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.